COMMUNIQUÉS West-GlobeNewswire

Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
07/05/2019
Updated results support lower risk of PML with extended interval dosing (EID; approximately every six weeks) for TYSABRI ® (natalizumab) in patients in a real-world setting New interim data further support safety and [...]
Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting
07/05/2019
MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial [...]
Allogene Therapeutics Reports First Quarter 2019 Financial Results
07/05/2019
Initiated ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Investigational New Drug (IND) Application Submitted to the U.S. Food & Drug Administration (FDA) for ALLO-715 [...]
Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update
07/05/2019
Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in second quarter of [...]
ReWalk Robotics Reports First Quarter 2019 Financial Results
07/05/2019
— 2019 first quarter total revenue of $1.6 million — — Gross margin record of 59% — — On track with ReStore Exo-Suit launch timeline — YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- ReWalk [...]
OpGen Announces Date of First Quarter 2019 Financial Results Conference Call
07/05/2019
GAITHERSBURG, Md., May 07, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its first quarter 2019 financial results after the close of the U.S. financial markets on [...]
Neuronetics Reports First Quarter 2019 Financial and Operating Results
07/05/2019
MALVERN, Pa., May 07, 2019 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for [...]
Aptinyx Appoints Henry Gosebruch to Its Board of Directors
07/05/2019
Chief Strategy Officer at AbbVie and former co-head of J.P. Morgan’s North American M&A Group becomes eighth member of Aptinyx board EVANSTON, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a [...]
Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer's Disease
07/05/2019
CLARKSVILLE, Md., May 07, 2019 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's [...]
TCR2 Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity of the Company’s Novel TRuC™-T Cells
07/05/2019
Preclinical study results published in Nature Communications show superior anti-tumor activity of T cell receptor fusion construct T cells (TRuC™)-T cells compared to chimeric antigen receptor (CAR)-T cells in several [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2019
07/05/2019
I n f ormation relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2019 Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : Euronext [...]
CORRECTION: ORION CORPORATION: ACQUISITION OF OWN SHARES 06.05.2019
07/05/2019
Orion Corporation NOTIFICATION 07.05.2019 at 09:45 CORRECTION: Total Price was incorrect in previous notification. Below is the correct release. ORION CORPORATION: ACQUISITION OF OWN SHARES 06.05.2019 Date 06.05.2019 [...]
CellaVision AB: Interim report January-March 2019
07/05/2019
Good performance in all regions generated strong organic growth January 1-March 31, 2019 Net sales increased by 34% to SEK 103.9 million (77.6). Organic growth was 31% (-20). Operating profit increased to SEK 34.9 [...]
Nexstim Plc: Offer shares have been registered
07/05/2019
Company announcement, Helsinki, 7 May 2019 at 9.00 AM Nexstim Plc: Offer shares have been registered Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( " Nexstim " or " Company " ), the targeted neuromodulation company developing and [...]
MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America
07/05/2019
$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones Leverages Vericel’s Commercial Capabilities and Presence in U.S. Burn Care Market Biologics License Application (BLA) Filing [...]
SPINEWAY : Réduction du capital social
07/05/2019
Réduction du capital social de Spineway Conformément à la deuxième et troisième résolutions de l’Assemblée Générale Mixte du 4 avril 2019, la Société Spineway a procédé à la réduction de capital social d’un montant de 2 [...]
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
07/05/2019
Nebulized ensifentrine as add-on to dual bronchodilator therapy for COPD demonstrated additional increase in lung function on top of maximum current therapy in three-day Phase 2 clinical trial Single dose of [...]
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
07/05/2019
LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2b [...]
Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
07/05/2019
Pivotal U.S. Phase 3 Clinical Study Met Primary and All Secondary Endpoints Highly Synergistic with Existing Commercial Franchise and Significantly Expands Vericel’s Presence in the Severe Burn Care Market CAMBRIDGE, [...]

Pages